Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 9/20 | 0.51 |
| ▸ | REN | P00797 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | F2 | P00734 | 1/20 | 0.51 |
| ▸ | LTA4H | P09960 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | PEPD | P12955 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
| ▸ | HRH1 | P35367 | 1/20 | 0.51 |
| ▸ | THPO | P40225 | 1/20 | 0.51 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | PREP | P48147 | 1/20 | 0.43 |
| ▸ | FAP | Q12884 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6559375 | 0.97 | ACE (0.54) | ACERENLMNAKDM4EF2 | |
| SCHEMBL2549572 | 0.97 | ACE (0.54) | ACERENLMNAKDM4EF2 | |
| SCHEMBL29384148 | 0.92 | ACE (0.49) | ACERENLMNAKDM4EF2 | |
| SCHEMBL30284899 | 0.90 | ACE (0.49) | ACERENLMNAKDM4EF2 | |
| SCHEMBL24580459 | 0.89 | ACE (0.54) | ACERENLMNAKDM4EF2 | |
| SCHEMBL29836001 | 0.89 | ACE (0.46) | ACERENLMNAKDM4EF2 | |
| SCHEMBL11378675 | 0.88 | PREP (0.57) | ACERENLMNAKDM4EF2 | |
| SCHEMBL11378678 | 0.88 | PREP (0.57) | ACERENLMNAKDM4EF2 | |
| SCHEMBL30235083 | 0.87 | ACE (0.47) | ACERENLMNAKDM4EF2 | |
| SCHEMBL30446492 | 0.87 | ACE (0.56) | ACERENLMNAKDM4EF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122031713-A | Preparation method and application of linker medicine and antibody-medicine conjugate thereof | 乐普生物科技股份有限公司 | 2026-05-15 | — | — | CN | claimed |
| EP-4659764-A1 | LINKER DRUG, AND PREPARATION METHOD AND USE OF ANTIBODY-DRUG CONJUGATE THEREOF | Lepu Biopharma Co., Ltd. (CN) | 2025-12-10 | — | — | EP | claimed |
| WO-2024160176-A1 | LINKER DRUG, AND PREPARATION METHOD AND USE OF ANTIBODY-DRUG CONJUGATE THEREOF | 上海美雅珂生物技术有限责任公司 | 2024-08-08 | — | — | WO | claimed |
| CN-122075733-A | Preparation method and application of linker medicine and antibody-medicine conjugate thereof | — | 2026-05-26 | — | — | CN | disclosed |
| CN-122031713-A | Preparation method and application of linker medicine and antibody-medicine conjugate thereof | 乐普生物科技股份有限公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20260042983-A1 | PROTEASES FOR BEER HAZE REDUCTION | INT N&H DENMARK APS (DK) | 2026-02-12 | — | — | US | disclosed |
| EP-4685235-A2 | PROTEASES FOR BEER HAZE REDUCTION | International N&H Denmark ApS (DK) | 2026-01-28 | — | — | EP | disclosed |
| EP-4685234-A2 | PROTEASES FOR BEER HAZE REDUCTION | International N&H Denmark ApS (DK) | 2026-01-28 | — | — | EP | disclosed |
| US-12503674-B2 | Proteases for beer haze reduction | INTERNATIONAL N&H DENMARK APS (DK) | 2025-12-23 | — | — | US | disclosed |
| EP-4660302-A2 | PROTEASES FOR BEER HAZE REDUCTION | International N&H Denmark ApS (DK) | 2025-12-10 | — | — | EP | disclosed |
| EP-4659764-A1 | LINKER DRUG, AND PREPARATION METHOD AND USE OF ANTIBODY-DRUG CONJUGATE THEREOF | Lepu Biopharma Co., Ltd. (CN) | 2025-12-10 | — | — | EP | disclosed |
| US-20250101350-A1 | PROTEASES FOR BEER HAZE REDUCTION | INTERNATIONAL N&H DENMARK APS (DK) | 2025-03-27 | — | — | US | disclosed |
| WO-2024160176-A1 | LINKER DRUG, AND PREPARATION METHOD AND USE OF ANTIBODY-DRUG CONJUGATE THEREOF | 上海美雅珂生物技术有限责任公司 | 2024-08-08 | — | — | WO | disclosed |
| US-20240228917-A1 | PROTEASES FOR BEER HAZE REDUCTION | INTERNATIONAL N&H DENMARK APS (DK) | 2024-07-11 | — | — | US | disclosed |
| CN-118043454-A | Protease for beer haze reduction | 国际N&H丹麦有限公司 | 2024-05-14 | — | — | CN | disclosed |
| EP-4355872-A2 | PROTEASES FOR BEER HAZE REDUCTION | International N&H Denmark ApS (DK) | 2024-04-24 | — | — | EP | disclosed |
| WO-2022266456-A2 | PROTEASES FOR BEER HAZE REDUCTION | DUPONT NUTRITION BIOSCIENCES APS (DK) | 2022-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260042983-A1 | PROTEASES FOR BEER HAZE REDUCTION | PREP, CPB2, MME | ACE 88/4885REN 448/4885LMNA 2235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.